RxDoctor Payments Data

Norma Devarie Diaz, MD

Cardiology · San Juan, PRNPI 1205812492

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,250 of the $7,631 with a category attached, or 68.8%. Pfizer Pharmaceuticals LLC accounts for 76.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $6,423 and has fallen 98.1% since, to $125 in 2025.

$7,631in general payments, 2019–2025

Across 31 payments — averaging $246.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer Pharmaceuticals LLC$6K
  • Johnson & Johnson$710
  • Boston Scientific$352
  • Amgen$270
  • Medtronic$153
  • E.r. Squibb & Sons, L.L.C.$150
  • plus $142 from 4 others

What the payments were for

  • Speaking & faculty fees$5,25069%
  • Travel & lodging$5307%
  • Food & beverage$1,85124%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer Pharmaceuticals LLC5$5,853
Johnson & Johnson12$710
Boston Scientific4$352
Amgen3$270
Medtronic1$153
E.r. Squibb & Sons, L.L.C.2$150
Pfizer1$69
AstraZeneca1$29
Biotronik Inc.1$24
PBG Puerto Rico LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$37,186
Medicare patients
90
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$114,365
FarxigaDapagliflozin Propanediol60$43,478
XareltoRivaroxaban62$43,073
Repatha SureclickEvolocumab71$41,155
Repatha PushtronexEvolocumab60$37,910
Candesartan Cilexetil401$31,019
Omega-3 Acid Ethyl Esters452$30,552
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid135$14,377
JardianceEmpagliflozin21$14,104
Ezetimibe847$12,248
Metoprolol Succinate746$11,075
EntrestoSacubitril/Valsartan15$10,407
Rosuvastatin Calcium842$8,602
Atorvastatin Calcium755$6,288
Amlodipine-ValsartanAmlodipine Besylate/Valsartan117$6,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$114,365165 claims
AstraZenecaFarxiga$29$43,47860 claims
Johnson & JohnsonXarelto$710$43,07362 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other cardiology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →